SCHEMBL4260191

SCHEMBL4260191

Cc1nc(-c2cnc3ccc(C=C4SC(=O)NC4=O)cn23)no1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 2/20 0.47
PIM1 P11309 9/20 0.44
PIM2 Q9P1W9 7/20 0.44
HPGD P15428 1/20 0.44
PIK3CA P42336 3/20 0.43
MGAM O43451 1/20 0.43
GAA P10253 1/20 0.43
SI P14410 1/20 0.43
MGAM2 Q2M2H8 1/20 0.43
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
HTT P42858 1/20 0.42
MTOR P42345 2/20 0.41
PIK3CB P42338 1/20 0.41
CDK19 Q9BWU1 1/20 0.41
CISD1 Q9NZ45 2/20 0.41
GSK3B P49841 2/20 0.41
MAOA P21397 1/20 0.41
PIM3 Q86V86 2/20 0.40
FLT3 P36888 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4260183 1.00 PIK3CG (0.47) PIK3CGPIM1PIM2HPGDPIK3CA
SCHEMBL13745282 0.79 PIK3CG (0.57) PIK3CGPIM1PIM2HPGDPIK3CA
SCHEMBL4256326 0.78 PIK3CG (0.47) PIK3CGPIM1PIM2HPGDPIK3CA
SCHEMBL4256322 0.78 PIK3CG (0.47) PIK3CGPIM1PIM2HPGDPIK3CA
SCHEMBL4260578 0.78 PIK3CA (0.46) PIM1PIK3CAMTORPIK3CBCDK19
SCHEMBL4251796 0.77 PIK3CG (0.57) PIK3CGPIM1PIM2HPGDPIK3CA
SCHEMBL4251800 0.77 PIK3CG (0.57) PIK3CGPIM1PIM2HPGDPIK3CA
SCHEMBL13745894 0.76 CISD1 (0.59) PIK3CGPIM1PIM2PIK3CAMGAM
SCHEMBL4250160 0.75 CISD1 (0.58) PIK3CGPIM1PIM2PIK3CAMGAM
SCHEMBL4250156 0.75 CISD1 (0.58) PIK3CGPIM1PIM2PIK3CAMGAM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215818-A1 THIOZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-08-27 US claimed
US-20090215818-A1 THIOZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-08-27 US disclosed
US-20090215818-A1 THIOZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-08-27 US disclosed
US-20090215818-A1 THIOZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-08-27 US disclosed
WO-2008014219-A2 THIOZOLIDINEDIONE DERIVATIVES AS P13 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215818-A1 THIOZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS PIK3CD, PI4KA, PIP4K2A PIK3CG 5/4885PIM1 103/4885PIM2 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.